 BRISBANE, Calif., Oct. 17, 2022 GLOBE NEWSWIRE -- Vera Therapeutics, Inc. Nasdaq: VERA, a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced two new abstracts featuring new clinical data on the Companys two product candidates, MAU868 in kidney transplant and atacicept in immunoglobulin A nephropathy IgAN. These data are to be presented in oral and poster sessions, respectively, at the American Society of Nephrology Kidney Week 2022 Annual Meeting, being held November 3-6, 2022 in Orlando, Florida. The oral presentation on MAU868 includes final results from the Phase 2 clinical trial of MAU868 versus placebo to treat BKV in kidney transplant patients. The poster presentation on atacicept includes a new analysis of previously presented clinical data from the Phase 2a JANUS clinical trial evaluating atacicept in patients with IgAN. 